Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma
NCT ID: NCT03642782
Last Updated: 2023-04-27
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
12 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-07-03
Study Completion Date
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Glaucoma is a common and potentially blinding disease. It is characterized by an optic nerve damage, a visual field defect and elevated intraocular pressure (IOP).
The loss of retinal nerve fibers is accompanied by functional impairment in the territories corresponding to deficits of the visual field. However, this structure-function relationship is not always found initially. These discrepancies are mainly chronological: the structural damage preceding the functional impairment sometimes of several years
The loss of retinal nerve fibers is accompanied by functional impairment in the territories corresponding to deficits of the visual field. However, this structure-function relationship is not always found initially. These discrepancies are mainly chronological: the structural damage preceding the functional impairment sometimes of several years
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Visual Function With a Portable Brain-computer Interface
NCT03760055
Glaucoma
Age Related Macular Degeneration
Optic Neuropathy
+1 more
UNKNOWN
Photographic Imaging of the Retina and Optic Nerve Head of Glaucoma Patients and Normal Controls
NCT00430274
Glaucoma
COMPLETED
oCular Examination at Cell RESolution With Optical TransmissionTomography
NCT06976034
Glaucoma Associated With Other Ocular Disorders
RECRUITING
NA
Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration
NCT06694272
Age Related Macular Degeneration
RECRUITING
Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy.
NCT06782997
Diabetic Retinopathy
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The electroretinogram pattern (ERGP) is an electrophysiological exploration technique that reflects the activity of retinal ganglion cells. It presents itself as an objective field of vision that does not require the active collaboration of the patient. It consists in recording the electrical activity of functional retinal ganglion cells following a light stimulation. Simple (30 minutes maximum), it could improve the detection of early forms of glaucoma. A significant ERGP is also thought to be correlated with peripapillary and macular CNP structural involvement of the ganglionic complex in early forms of glaucoma (MD\> -6 dB).
Some results even suggest that ganglion dysfunction could be detected by the ERGP eight years on average before the occurrence of detectable alterations on the RNFL OCT. ERGP is already recognized as a routine examination for monitoring glaucomatous patients (review side in nomenclature and reimbursed by Social Security) but it could therefore be used as a diagnostic tool in very early forms of intraocular hypertonia glaucoma so to objectify signs of preperimetric functional impairment in order to establish a suitable hypotonizing treatment and to improve the prognosis of this disease.
Some results even suggest that ganglion dysfunction could be detected by the ERGP eight years on average before the occurrence of detectable alterations on the RNFL OCT. ERGP is already recognized as a routine examination for monitoring glaucomatous patients (review side in nomenclature and reimbursed by Social Security) but it could therefore be used as a diagnostic tool in very early forms of intraocular hypertonia glaucoma so to objectify signs of preperimetric functional impairment in order to establish a suitable hypotonizing treatment and to improve the prognosis of this disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Glaucoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
early age of glaucoma or with important risk factors
All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
Group Type
EXPERIMENTAL
Electroretinogram Pattern (Diopsys® NOVA System)
Intervention Type
DEVICE
it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electroretinogram Pattern (Diopsys® NOVA System)
it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Man and woman age ≥ 18 years
* Francophone
* Patient with medical insurance
* Refraction: sphere ± 5.0 D and cylinder ± 3.0 D
* Pupillary diameter ≥ 3mm
* Early glaucoma patients :
* Intraocular pressure\> 21 mmHg or \<21mmHg under treatment
* Thickness of pathological retinal nerve fibers with at least one affected area (OCT)
* At least one reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and no artifacts, with Corrected Pattern Standard Deviation (CPSD) pathological in the 5% and Glaucoma Hemifield Pathological test and an early attack (MD\> -6dB)
* Patient at risk for glaucoma with:
* And / or family history of glaucoma
* and / or intraocular pressure\> 21 mmHg
* and / or retinal nerve fibers (pathological thickness in at least one area on the OCT)
* and / or reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and without artifact, with pathological Corrected Pattern Standard Deviation (CPSD) in the 5% and Glaucoma Hemifield Pathological Test and an early onset (MD\> -6 dB).
* Francophone
* Patient with medical insurance
* Refraction: sphere ± 5.0 D and cylinder ± 3.0 D
* Pupillary diameter ≥ 3mm
* Early glaucoma patients :
* Intraocular pressure\> 21 mmHg or \<21mmHg under treatment
* Thickness of pathological retinal nerve fibers with at least one affected area (OCT)
* At least one reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and no artifacts, with Corrected Pattern Standard Deviation (CPSD) pathological in the 5% and Glaucoma Hemifield Pathological test and an early attack (MD\> -6dB)
* Patient at risk for glaucoma with:
* And / or family history of glaucoma
* and / or intraocular pressure\> 21 mmHg
* and / or retinal nerve fibers (pathological thickness in at least one area on the OCT)
* and / or reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and without artifact, with pathological Corrected Pattern Standard Deviation (CPSD) in the 5% and Glaucoma Hemifield Pathological Test and an early onset (MD\> -6 dB).
Exclusion Criteria
* Visual acuity below 20/30 (Snellen scale or equivalent on another visual acuity scale)
* Unreliable visual field (false positives, loss of fixation and false negatives\> 25%)
* History of intraocular surgery (except uncomplicated cataract surgery)
* Ocular pathology other than associated glaucoma
* Neurological disease affecting the visual field or the optic nerve
* History of macular laser or pan retinal photocoagulation
* Unreliable ERGP pattern
* Offset OCT, unreliable
* Refusal to participate in the study
* Patient under tutorship or curatorship
* Patient deprived of liberty
* Epileptic patient
* Eczema of the eyelids or allergy to one of the components of the electrodes or skin gel allowing the cleaning of the skin before the positioning of the electrodes.
* Unreliable visual field (false positives, loss of fixation and false negatives\> 25%)
* History of intraocular surgery (except uncomplicated cataract surgery)
* Ocular pathology other than associated glaucoma
* Neurological disease affecting the visual field or the optic nerve
* History of macular laser or pan retinal photocoagulation
* Unreliable ERGP pattern
* Offset OCT, unreliable
* Refusal to participate in the study
* Patient under tutorship or curatorship
* Patient deprived of liberty
* Epileptic patient
* Eczema of the eyelids or allergy to one of the components of the electrodes or skin gel allowing the cleaning of the skin before the positioning of the electrodes.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Hôpital Saint-Joseph
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Paris Saint-Joseph
Paris, , France
Site Status
Countries
Review the countries where the study has at least one active or historical site.
France
References
Explore related publications, articles, or registry entries linked to this study.
Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714.
Reference Type
RESULT
Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol. 1989 May 15;107(5):453-64. doi: 10.1016/0002-9394(89)90488-1.
Reference Type
RESULT
Harwerth RS, Quigley HA. Visual field defects and retinal ganglion cell losses in patients with glaucoma. Arch Ophthalmol. 2006 Jun;124(6):853-9. doi: 10.1001/archopht.124.6.853.
Reference Type
RESULT
Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, Witt KA. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991 Jan;109(1):77-83. doi: 10.1001/archopht.1991.01080010079037.
Reference Type
RESULT
Hwang YH, Kim YY, Kim HK, Sohn YH. Ability of cirrus high-definition spectral-domain optical coherence tomography clock-hour, deviation, and thickness maps in detecting photographic retinal nerve fiber layer abnormalities. Ophthalmology. 2013 Jul;120(7):1380-7. doi: 10.1016/j.ophtha.2012.12.048. Epub 2013 Mar 28.
Reference Type
RESULT
Tan O, Chopra V, Lu AT, Schuman JS, Ishikawa H, Wollstein G, Varma R, Huang D. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009 Dec;116(12):2305-14.e1-2. doi: 10.1016/j.ophtha.2009.05.025. Epub 2009 Sep 10.
Reference Type
RESULT
Na JH, Lee K, Lee JR, Baek S, Yoo SJ, Kook MS. Detection of macular ganglion cell loss in preperimetric glaucoma patients with localized retinal nerve fibre defects by spectral-domain optical coherence tomography. Clin Exp Ophthalmol. 2013 Dec;41(9):870-80. doi: 10.1111/ceo.12142. Epub 2013 Jul 5.
Reference Type
RESULT
Mwanza JC, Oakley JD, Budenz DL, Anderson DR; Cirrus Optical Coherence Tomography Normative Database Study Group. Ability of cirrus HD-OCT optic nerve head parameters to discriminate normal from glaucomatous eyes. Ophthalmology. 2011 Feb;118(2):241-8.e1. doi: 10.1016/j.ophtha.2010.06.036. Epub 2010 Oct 28.
Reference Type
RESULT
Hwang YH, Kim YY. Glaucoma diagnostic ability of quadrant and clock-hour neuroretinal rim assessment using cirrus HD optical coherence tomography. Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2226-34. doi: 10.1167/iovs.11-8689.
Reference Type
RESULT
De Jong LA, Snepvangers CE, van den Berg TJ, Langerhorst CT. Blue-yellow perimetry in the detection of early glaucomatous damage. Doc Ophthalmol. 1990 Oct;75(3-4):303-14. doi: 10.1007/BF00164844.
Reference Type
RESULT
Felius J, de Jong LA, van den Berg TJ, Greve EL. Functional characteristics of blue-on-yellow perimetric thresholds in glaucoma. Invest Ophthalmol Vis Sci. 1995 Jul;36(8):1665-74.
Reference Type
RESULT
Sample PA, Taylor JD, Martinez GA, Lusky M, Weinreb RN. Short-wavelength color visual fields in glaucoma suspects at risk. Am J Ophthalmol. 1993 Feb 15;115(2):225-33. doi: 10.1016/s0002-9394(14)73928-5.
Reference Type
RESULT
Anderson AJ, Johnson CA. Frequency-doubling technology perimetry. Ophthalmol Clin North Am. 2003 Jun;16(2):213-25. doi: 10.1016/s0896-1549(03)00011-7.
Reference Type
RESULT
Anderson AJ, Johnson CA, Fingeret M, Keltner JL, Spry PG, Wall M, Werner JS. Characteristics of the normative database for the Humphrey matrix perimeter. Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1540-8. doi: 10.1167/iovs.04-0968.
Reference Type
RESULT
Artes PH, Hutchison DM, Nicolela MT, LeBlanc RP, Chauhan BC. Threshold and variability properties of matrix frequency-doubling technology and standard automated perimetry in glaucoma. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2451-7. doi: 10.1167/iovs.05-0135.
Reference Type
RESULT
Mafei L, Fiorentini A. Electroretinographic responses to alternating gratings before and after section of the optic nerve. Science. 1981 Feb 27;211(4485):953-5. doi: 10.1126/science.7466369.
Reference Type
RESULT
Bowd C, Tafreshi A, Zangwill LM, Medeiros FA, Sample PA, Weinreb RN. Pattern electroretinogram association with spectral domain-OCT structural measurements in glaucoma. Eye (Lond). 2011 Feb;25(2):224-32. doi: 10.1038/eye.2010.203. Epub 2010 Dec 24.
Reference Type
RESULT
Bowd C, Tafreshi A, Vizzeri G, Zangwill LM, Sample PA, Weinreb RN. Repeatability of pattern electroretinogram measurements using a new paradigm optimized for glaucoma detection. J Glaucoma. 2009 Aug;18(6):437-42. doi: 10.1097/IJG.0b013e31818c6f44.
Reference Type
RESULT
Bowd C, Vizzeri G, Tafreshi A, Zangwill LM, Sample PA, Weinreb RN. Diagnostic accuracy of pattern electroretinogram optimized for glaucoma detection. Ophthalmology. 2009 Mar;116(3):437-43. doi: 10.1016/j.ophtha.2008.10.026. Epub 2009 Jan 22.
Reference Type
RESULT
Tafreshi A, Racette L, Weinreb RN, Sample PA, Zangwill LM, Medeiros FA, Bowd C. Pattern electroretinogram and psychophysical tests of visual function for discriminating between healthy and glaucoma eyes. Am J Ophthalmol. 2010 Mar;149(3):488-95. doi: 10.1016/j.ajo.2009.09.027.
Reference Type
RESULT
Ventura LM, Porciatti V. Restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction: a pilot study. Ophthalmology. 2005 Jan;112(1):20-7. doi: 10.1016/j.ophtha.2004.09.002.
Reference Type
RESULT
Bach M, Unsoeld AS, Philippin H, Staubach F, Maier P, Walter HS, Bomer TG, Funk J. Pattern ERG as an early glaucoma indicator in ocular hypertension: a long-term, prospective study. Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4881-7. doi: 10.1167/iovs.05-0875.
Reference Type
RESULT
Ventura LM, Sorokac N, De Los Santos R, Feuer WJ, Porciatti V. The relationship between retinal ganglion cell function and retinal nerve fiber thickness in early glaucoma. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3904-11. doi: 10.1167/iovs.06-0161.
Reference Type
RESULT
Banitt MR, Ventura LM, Feuer WJ, Savatovsky E, Luna G, Shif O, Bosse B, Porciatti V. Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2346-52. doi: 10.1167/iovs.12-11026.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIOPSYS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
High Resolution, High-speed Multimodal Ophthalmic Imaging
NCT04129021
RECRUITING
NA
Intelligent Evaluation of Diabetic Retinopathy
NCT04624737
COMPLETED
NA
Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients
NCT07056738
ENROLLING_BY_INVITATION
Smartphone-based Ophthalmoscopy
NCT02177747
COMPLETED
NA
Analysis of Visual Pathways in Glaucoma Patients Using a 3tesla-MRI
NCT01621841
COMPLETED
Multimodal Imaging in Vitreo-retinal Surgery and Macular Dystrophies
NCT05747144
RECRUITING
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
NCT06351657
RECRUITING
AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma
NCT07318428
NOT_YET_RECRUITING
NA
Reproducibility of Retinal Nerve Fiber Layer Thickness Measurements Using the Eye Tracker and Retest Function of Spectralis® SD-OCT in Glaucomatous Eyes and Healthy Controls
NCT01228721
TERMINATED
PHASE4
Fundus Camera Module for Early Detection of Alzheimer's Disease
NCT06841848
RECRUITING
Early Diagnosis in Glaucoma With GDxVcc
NCT01022281
COMPLETED
Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases
NCT07143851
NOT_YET_RECRUITING
Building Research With Artificial Intelligence in Neuro-Ophthalmology
NCT06390579
COMPLETED
AutoDx-DR Prospective Clinical Validation Study Protocol
NCT04627272
UNKNOWN
NA
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
NCT00748384
COMPLETED
Retinal Imaging With Oblique Illumination
NCT04398394
COMPLETED
NA
Pupillometry Dynamic Measures in Patients Without Ocular or Neurological Disease
NCT02894281
COMPLETED
Bimodal and Coaxial High Resolution Ophtalmic Imaging
NCT04620876
UNKNOWN
NA
Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA
NCT03415984
COMPLETED
Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients
NCT02863640
TERMINATED
Validation of an Automatic Analysis Algorithm of the Probability of Glaucoma From Optic Disc Images
NCT04972695
COMPLETED
Optic Neuritis and Ganglion Cell Layer
NCT02864134
COMPLETED
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
NCT00884637
COMPLETED
OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases
NCT05752045
UNKNOWN
NA